1. Home
  2. FSBW vs CBIO Comparison

FSBW vs CBIO Comparison

Compare FSBW & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSBW
  • CBIO
  • Stock Information
  • Founded
  • FSBW 1936
  • CBIO 2003
  • Country
  • FSBW United States
  • CBIO United States
  • Employees
  • FSBW N/A
  • CBIO N/A
  • Industry
  • FSBW Banks
  • CBIO
  • Sector
  • FSBW Finance
  • CBIO
  • Exchange
  • FSBW Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • FSBW 324.8M
  • CBIO 308.0M
  • IPO Year
  • FSBW 2012
  • CBIO N/A
  • Fundamental
  • Price
  • FSBW $40.14
  • CBIO $13.79
  • Analyst Decision
  • FSBW Hold
  • CBIO Strong Buy
  • Analyst Count
  • FSBW 1
  • CBIO 4
  • Target Price
  • FSBW $44.00
  • CBIO $25.50
  • AVG Volume (30 Days)
  • FSBW 13.9K
  • CBIO 92.1K
  • Earning Date
  • FSBW 07-22-2025
  • CBIO 07-31-2025
  • Dividend Yield
  • FSBW 2.79%
  • CBIO N/A
  • EPS Growth
  • FSBW N/A
  • CBIO N/A
  • EPS
  • FSBW 4.15
  • CBIO N/A
  • Revenue
  • FSBW $139,676,000.00
  • CBIO N/A
  • Revenue This Year
  • FSBW $9.62
  • CBIO N/A
  • Revenue Next Year
  • FSBW $5.35
  • CBIO N/A
  • P/E Ratio
  • FSBW $9.66
  • CBIO N/A
  • Revenue Growth
  • FSBW 0.61
  • CBIO N/A
  • 52 Week Low
  • FSBW $34.61
  • CBIO $10.83
  • 52 Week High
  • FSBW $49.15
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • FSBW 50.46
  • CBIO N/A
  • Support Level
  • FSBW $37.22
  • CBIO N/A
  • Resistance Level
  • FSBW $41.46
  • CBIO N/A
  • Average True Range (ATR)
  • FSBW 1.27
  • CBIO 0.00
  • MACD
  • FSBW 0.15
  • CBIO 0.00
  • Stochastic Oscillator
  • FSBW 72.15
  • CBIO 0.00

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: